Autophagy potential of polyphenols in breast carcinoma: A systematic review.

Pathol Res PractJul 9, 2026 (epub)
Clinical ResearchOncology (Medical)

Asal Golchin, Shirin Teymori Nobari, Masomeh Maleki et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the effects of polyphenols on autophagy in breast cancer, analyzing 48 studies, including 40 in vitro and 8 in vivo. Key findings indicate that curcumin, resveratrol, and carnosol effectively modulate autophagy pathways, with curcumin enhancing autophagic flux and resveratrol inhibiting tumor growth. However, translating these results to clinical outcomes remains challenging.

Key findings

  • Curcumin modulated the PI3K/AKT/mTOR pathway, enhancing autophagic flux and reducing cell viability.
  • Resveratrol consistently suppressed cancer stem-like cells and inhibited tumor growth in xenografted models.
  • Carnosol induced autophagy by degrading STAT3 and downregulating p62, inhibiting metastasis and tumor growth.

Why it matters

Understanding the role of polyphenols in autophagy could inform future therapeutic strategies in breast cancer treatment. However, the challenge lies in translating these in vitro findings into effective clinical applications.

Source

Published in Pathol Res Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.